Background. Dalbavancin is a lipoglycopeptide antibiotic with activity against Gram-positive pathogens and a long half-life allowing for weekly dosing. DISCOVER 1 and 2 were identically designed clinical trials of dalbavancin vs vancomycin (VAN) with option to switch to oral linezolid for the treatment of ABSSSI. We evaluated outcomes of ABSSSI in patients treated with VAN by dosing regimen utilized and serum trough concentrations for VAN.
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Methods. Both trials were double-blind, double dummy, pharmacist-unblinded randomized trials in which patients with ABSSSI were randomized to receive dalbavancin 1g IV on Day 1 and 500 mg IV on Day 8 or VAN 1g (or 15mg/kg) IV every 12 hours (q12h) for at least 3 days with an option to switch to oral linezolid 600 mg q12h to complete 10-14 days of therapy. The primary endpoint was measured at 48-72 hours of therapy with success requiring cessation of spread of the infection and absence of fever. Secondary endpoints included clinical status at the end of therapy. Outcomes by fixed vs weight-based dosing regimens of VAN and outcomes by serum VAN trough concentrations were analyzed.
Results. Please see Tables 1 and 2 . 
